- Home
- TRVI vs JQC Comparison
TRVI vs JQC Comparison
Compare TRVI & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- JQC
- Stock Information
- Founded
- TRVI 2011
- JQC 2003
- Country
- TRVI United States
- JQC United States
- Employees
- TRVI N/A
- JQC N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- JQC Finance Companies
- Sector
- TRVI Health Care
- JQC Finance
- Exchange
- TRVI Nasdaq
- JQC Nasdaq
- Market Cap
- TRVI 725.7M
- JQC 730.7M
- IPO Year
- TRVI 2019
- JQC N/A
- Fundamental
- Price
- TRVI $6.55
- JQC $5.48
- Analyst Decision
- TRVI Strong Buy
- JQC
- Analyst Count
- TRVI 9
- JQC 0
- Target Price
- TRVI $19.94
- JQC N/A
- AVG Volume (30 Days)
- TRVI 1.6M
- JQC 714.6K
- Earning Date
- TRVI 08-07-2025
- JQC 01-01-0001
- Dividend Yield
- TRVI N/A
- JQC 11.13%
- EPS Growth
- TRVI N/A
- JQC N/A
- EPS
- TRVI N/A
- JQC N/A
- Revenue
- TRVI N/A
- JQC N/A
- Revenue This Year
- TRVI N/A
- JQC N/A
- Revenue Next Year
- TRVI N/A
- JQC N/A
- P/E Ratio
- TRVI N/A
- JQC N/A
- Revenue Growth
- TRVI N/A
- JQC N/A
- 52 Week Low
- TRVI $2.36
- JQC $4.82
- 52 Week High
- TRVI $7.48
- JQC $5.65
- Technical
- Relative Strength Index (RSI)
- TRVI 61.06
- JQC 68.31
- Support Level
- TRVI $5.41
- JQC $5.42
- Resistance Level
- TRVI $6.08
- JQC $5.49
- Average True Range (ATR)
- TRVI 0.32
- JQC 0.03
- MACD
- TRVI 0.09
- JQC 0.01
- Stochastic Oscillator
- TRVI 96.20
- JQC 93.75
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.